Visualitzant per títol

First universal newborn screening program for severe combined immunodeficiency in Europe: two-years' experience in Catalonia (Spain)

Argudo-Ramírez, Ana; Martín Nalda, Andrea; Pajares Garcia, Sonia; García Prat, Marina; Colobran Oriol, Roger; Rivière, Jacques; Soler Palacín, Pere; Marin Soria, José Luis; Lopez Galera, Rosa Maria; González de Aledo Castillo, José Manuel; Martínez Gallo, Mónica (Frontiers Media, 2019-10-22)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga, Malaka; Braña Garcia, Irene; Bono, Petri; Postel-Vinay, Sophie; Plummer, Ruth; Aspegren, John (Springer Nature, 2020-12-08)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Yap, Timothy A.; Vieito Villar, Maria; Baldini, Capucine; Sepúlveda, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo (American Association for Cancer Research, 2021-12)

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Salamero García, Olga; Willekens, Christophe; Pérez-Simón, José Antonio; Pigneux, Arnaud; Récher, Christian; Carpio Segura, Cecilia Carmen; Bosch Albareda, Francesc; Montesinos, Pau (American Society of Clinical Oncology, 2020-12-20)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Piha-Paul, Sarina; Geva, Ravit; Tan, Tira; Lim, Darren Wan-Teck; Hierro Carbó, Cinta; Doi, Toshikiko (BMJ, 2021-08)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Davis, Elizabeth J; Martín Liberal, Juan Jesús; Kristeleit, Rebecca S; Cho, Daniel; Blagden, Sarah P; Berthold, Dominik; Vieito Villar, Maria (BMJ, 2022-10)

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Boyiadzis, Michael; Desai, Pinkal; Daskalakis, Nikki; Donnellan, William; Ferrante, Lucille; Goldberg, Jenna D.; Salamero García, Olga (Wiley, 2023-03)

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Narayan, Rupa; Alfonso-Piérola, Ana; Donnellan, William; Abdul-Hay, Maher; Molero , Antonieta; Platzbecker, Uwe (Wiley, 2024-03-18)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

Martín Liberal, Juan Jesús; Hollebecque, Antoine; Jungels, Christiane; Martin-Romano, Patricia; Rodon Ahnert, Jordi; Aftimos, Philippe (Springer Nature, 2020-10)

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Felip Font, Enriqueta; Morgensztern, Daniel; Trigo, José Manuel; Curigliano, Giuseppe; Rutkowski, Piotr; Moreno, Victor (Springer, 2022-04)

First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study

Vidal-Jove, Joan; Serres Créixams, Xavier; Vlaisavljevich, Eli; Cannata, Jon; Duryea, Alex; Miller, Ryan; Merino Casabiel, Xavier (Taylor & Francis, 2022)

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

Prager, Gerald W; Westphalen, C Benedikt; D'Esquermes, Nathalie; Ferreras, Anabel; Macarulla Mercadé, Teresa; Taieb, Julien; Melisi, Davide (BMJ, 2020-01-20)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Ready, Neal; Audigier-Valette, Clarisse; Goldman, Jonathan W.; Felip Font, Enriqueta; Ciuleanu, Tudor; Garcia Campelo, Rosario (BMJ, 2023-02)

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, Luis; Bennouna, Jaafar; Schenker, Michael; Cheng, Ying; FELIP, ENRIQUETA; Cobo, Manuel; Ciuleanu, Tudor Eliade (Elsevier, 2023-02)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Reck, M.; Ciuleanu, Tudor; Schenker, M.; Zurawski, B.; Menezes, J.; Felip Font, Enriqueta; Cobo, Manuel (Elsevier, 2021-10)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Gonzalez-Martin, Antonio; Harter, Philipp; Lorusso, Domenica; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Banerjee, Susana (BMJ, 2020-12-11)

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Fizazi, Karim; Fay, Andre P; De Giorgi, Ugo; Azad, Arun; Carles, Joan; Matsubara, Nobuaki (Nature Portfolio, 2024-01)

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Springer Nature, 2022-06-01)

First-trimester screening for pre-eclampsia and small for gestational age: A comparison of the gaussian and Fetal Medicine Foundation algorithms

Serrano Sanchez, Berta; Rodó Rodríguez, Carlota; García Manau, Pablo; Sánchez Durán, Maria Ángeles; Pancorbo Lerma, Maria Luisa; Forcada, Cristina; Murcia-Oliveras, Maria-Teresa; Perestelo Abreu, Ana Margarita; Armengol Alsina, Mireia; Mendoza Cobaleda, Manel; Carreras Moratonas, Elena; Bonacina, Erika (Wiley, 2023-01)

Fitxa terapèutica: faringitis/amigdalitis aguda

Grup de Treball VINCat PROA Primària (Servei Català de la Salut, 2022)

Scientia. Dipòsit d'Informació Digital del Departament de Salut